RessTargeting the HGF/MeT axis in oncologyPhase III trial of erlotinib
RessTargeting the HGF/MeT axis in oncologyPhase III trial of erlotinib ?tivantinib in pretreated, nonsquamous NSCLC sufferers was initiated. While a considerable improvement in PFS for the combination therapy was observed,…